FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309603945> ?p ?o ?g. }

• W4309603945 abstract "Background: Gout is a common arthritis, due to deposition of monosodium urate (MSU) crystals which results in IL-1β secretion by tissue-resident macrophages. Xanthine oxidase (XO) catalyzes uric acid (UA) production and in the process, reactive oxygen species (ROS) are generated which contributes to NLRP3 inflammasome activation. Protein phosphatase 2A (PP2A) may be involved in regulating inflammatory pathways in macrophages. The objective of this study was to investigate whether PP2A regulates gout inflammation, mediated by XO activity modulation. We studied UA and ROS generations in MSU stimulated murine bone marrow derived macrophages (BMDMs) in response to fingolimod phosphate, a PP2A activator, and compared its anti-inflammatory efficacy to that of an XO inhibitor, febuxostat. Methods: BMDMs were stimulated with MSU, GM-CSF/IL-1β or nigericin ± fingolimod (2.5 μM) or febuxostat (200 μM) and UA levels, ROS, XO, and PP2A activities, Xdh (XO) expression and secreted IL-1β levels were determined. PP2A activity and IL-1β in MSU stimulated BMDMs ± N-acetylcysteine (NAC) (10 μM) ± okadaic acid (a PP2A inhibitor) were also determined. M1 polarization of BMDMs in response to MSU ± fingolimod treatment was assessed by a combination of iNOS expression and multiplex cytokine assay. The in vivo efficacy of fingolimod was assessed in a murine peritoneal model of acute gout where peritoneal lavages were studied for pro-inflammatory classical monocytes (CMs), anti-inflammatory nonclassical monocytes (NCMs) and neutrophils by flow cytometry and IL-1β by ELISA. Results: Fingolimod reduced intracellular and secreted UA levels (p < 0.05), Xdh expression (p < 0.001), XO activity (p < 0.001), ROS generation (p < 0.0001) and IL-1β secretion (p < 0.0001), whereas febuxostat enhanced PP2A activity (p < 0.05). NAC treatment enhanced PP2A activity and reduced XO activity and PP2A restoration mediated NAC's efficacy as co-treatment with okadaic acid increased IL-1β secretion (p < 0.05). Nigericin activated caspase-1 and reduced PP2A activity (p < 0.001) and fingolimod reduced caspase-1 activity in BMDMs (p < 0.001). Fingolimod reduced iNOS expression (p < 0.0001) and secretion of IL-6 and TNF-α (p < 0.05). Fingolimod reduced CMs (p < 0.0001), neutrophil (p < 0.001) and IL-1β (p < 0.05) lavage levels while increasing NCMs (p < 0.001). Conclusion: Macrophage PP2A is inactivated in acute gout by ROS and a PP2A activator exhibited a broad anti-inflammatory effect in acute gout in vitro and in vivo." @default.
• W4309603945 created "2022-11-28" @default.
• W4309603945 creator A5083663000 @default.
• W4309603945 creator A5086816730 @default.
• W4309603945 date "2022-11-17" @default.
• W4309603945 modified "2023-10-01" @default.
• W4309603945 title "Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model" @default.
• W4309603945 cites W1509128008 @default.
• W4309603945 cites W1883292020 @default.
• W4309603945 cites W1929024384 @default.
• W4309603945 cites W1975015556 @default.
• W4309603945 cites W1976312989 @default.
• W4309603945 cites W1984288637 @default.
• W4309603945 cites W2003407110 @default.
• W4309603945 cites W2009800174 @default.
• W4309603945 cites W2018643167 @default.
• W4309603945 cites W2022078450 @default.
• W4309603945 cites W2032350680 @default.
• W4309603945 cites W2043168039 @default.
• W4309603945 cites W2045895870 @default.
• W4309603945 cites W2048827030 @default.
• W4309603945 cites W2049267620 @default.
• W4309603945 cites W2054571187 @default.
• W4309603945 cites W2107277218 @default.
• W4309603945 cites W2136722399 @default.
• W4309603945 cites W2145066076 @default.
• W4309603945 cites W2192080449 @default.
• W4309603945 cites W2206815231 @default.
• W4309603945 cites W2306899700 @default.
• W4309603945 cites W2315844347 @default.
• W4309603945 cites W2551297080 @default.
• W4309603945 cites W2576559149 @default.
• W4309603945 cites W2772575461 @default.
• W4309603945 cites W2773337571 @default.
• W4309603945 cites W2903108867 @default.
• W4309603945 cites W2910690328 @default.
• W4309603945 cites W2910951675 @default.
• W4309603945 cites W2912278776 @default.
• W4309603945 cites W2921637388 @default.
• W4309603945 cites W2943293743 @default.
• W4309603945 cites W2944991703 @default.
• W4309603945 cites W3014992600 @default.
• W4309603945 cites W3027031175 @default.
• W4309603945 cites W3033707087 @default.
• W4309603945 cites W3036390458 @default.
• W4309603945 cites W3107444224 @default.
• W4309603945 cites W3126269755 @default.
• W4309603945 cites W4200533960 @default.
• W4309603945 cites W4231686634 @default.
• W4309603945 cites W4284895806 @default.
• W4309603945 doi "https://doi.org/10.3389/fphar.2022.1033520" @default.
• W4309603945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467056" @default.
• W4309603945 hasPublicationYear "2022" @default.
• W4309603945 type Work @default.
• W4309603945 citedByCount "7" @default.
• W4309603945 countsByYear W43096039452023 @default.
• W4309603945 crossrefType "journal-article" @default.
• W4309603945 hasAuthorship W4309603945A5083663000 @default.
• W4309603945 hasAuthorship W4309603945A5086816730 @default.
• W4309603945 hasBestOaLocation W43096039451 @default.
• W4309603945 hasConcept C162157009 @default.
• W4309603945 hasConcept C164027704 @default.
• W4309603945 hasConcept C181199279 @default.
• W4309603945 hasConcept C185592680 @default.
• W4309603945 hasConcept C203014093 @default.
• W4309603945 hasConcept C2776914184 @default.
• W4309603945 hasConcept C2777209026 @default.
• W4309603945 hasConcept C2778102346 @default.
• W4309603945 hasConcept C2779719074 @default.
• W4309603945 hasConcept C2779721657 @default.
• W4309603945 hasConcept C2779881121 @default.
• W4309603945 hasConcept C2780932893 @default.
• W4309603945 hasConcept C48349386 @default.
• W4309603945 hasConcept C55493867 @default.
• W4309603945 hasConcept C71924100 @default.
• W4309603945 hasConcept C98274493 @default.
• W4309603945 hasConceptScore W4309603945C162157009 @default.
• W4309603945 hasConceptScore W4309603945C164027704 @default.
• W4309603945 hasConceptScore W4309603945C181199279 @default.
• W4309603945 hasConceptScore W4309603945C185592680 @default.
• W4309603945 hasConceptScore W4309603945C203014093 @default.
• W4309603945 hasConceptScore W4309603945C2776914184 @default.
• W4309603945 hasConceptScore W4309603945C2777209026 @default.
• W4309603945 hasConceptScore W4309603945C2778102346 @default.
• W4309603945 hasConceptScore W4309603945C2779719074 @default.
• W4309603945 hasConceptScore W4309603945C2779721657 @default.
• W4309603945 hasConceptScore W4309603945C2779881121 @default.
• W4309603945 hasConceptScore W4309603945C2780932893 @default.
• W4309603945 hasConceptScore W4309603945C48349386 @default.
• W4309603945 hasConceptScore W4309603945C55493867 @default.
• W4309603945 hasConceptScore W4309603945C71924100 @default.
• W4309603945 hasConceptScore W4309603945C98274493 @default.
• W4309603945 hasFunder F4320337362 @default.
• W4309603945 hasLocation W43096039451 @default.
• W4309603945 hasLocation W43096039452 @default.
• W4309603945 hasLocation W43096039453 @default.
• W4309603945 hasLocation W43096039454 @default.
• W4309603945 hasOpenAccess W4309603945 @default.
• W4309603945 hasPrimaryLocation W43096039451 @default.
• W4309603945 hasRelatedWork W2032154463 @default.

• next